Atorvastatin

Generic Name: Atorvastatin

Brand Names: Atorvaliq, Caduet, Lipitor, Lypqozet

Drug Type: Small Molecule

Chemical Formula: C_₃₃H_₃₅FN_₂O_₅

CAS Number: 134523-00-5

Unique Ingredient Identifier: A0JWA85V8F

Background: Atorvastatin (Lipitor®), is a lipid-lowering drug included in the statin class of medications. By inhibiting the endogenous production of cholesterol in the liver, statins lower abnormal cholesterol and lipid levels, and ultimately reduce the risk of cardiovascular disease. More specifically, statin medications competitively inhibit the enzyme hydroxymethylg...

Indication: Atorvastatin is indicated for the treatment of several types of dyslipidemias, including primary hyperlipidemia and mixed dyslipidemia in adults, hypertriglyceridemia, primary dysbetalipoproteinemia, homozygous familial hypercholesterolemia, and heterozygous familial hypercholesterolemia in adolescent patients with failed dietary modifications.
...

Associated Conditions: Anginal Pain, Cardiovascular Complications, Cardiovascular Disease (CVD), Coronary Artery Disease (CAD), Coronary artery thrombosis, Dysbetalipoproteinemia, Fredrickson Type III lipidemia, Heterozygous Familial Hypercholesterolemia (HeFH), High Cholesterol, Homozygous Familial Hypercholesterolaemia (HoFH), Hospitalizations, Hypertension, Essential Hypertension, Hypertriglyceridemias, Mixed Dyslipidemias, Mixed Hyperlipidemia, Myocardial Infarction, Non-familial hypercholesterolemia, Nonfatal Myocardial Infarction, Postoperative Thromboembolism, Primary Hypercholesterolemia, Stroke, Thrombosis, Transient Ischemic Attack, Elevation of serum triglyceride levels, Heterozygous familial hyperlipidemia, Non-familial hyperlipidemia, Primary Hyperlipidemia, Revascularization procedures

Associated Therapies: -

Clinical Trials

Myocardial Infarction Size Reduction With Atorvastatin

Phase 4

Completed

Conditions: Myocardial Infarction
Reperfusion Injury

First Posted Date: 2006-02-03

Last Posted Date: 2008-05-21

Lead Sponsor: R&D Cardiologie

Target Recruit Count: 50

Registration Number: NCT00286312

Locations: 🇳🇱
University Medical Centre Utrecht, Utrecht, Netherlands
🇳🇱
St. Antonius Hospital, Nieuwegein, Netherlands

Atorvastatin to Treat Pulmonary Sarcoidosis

Phase 2

Completed

Conditions: Sarcoidosis, Pulmonary

Interventions: Other: Placebo Oral Tablet
Drug: Atorvastatin

First Posted Date: 2006-01-19

Last Posted Date: 2017-05-22

Lead Sponsor: National Heart, Lung, and Blood Institute (NHLBI)

Target Recruit Count: 55

Registration Number: NCT00279708

Locations: 🇺🇸
National Institutes of Health Clinical Center, 9000 Rockville Pike, Bethesda, Maryland, United States

To Evaluate Ezetimibe Plus Atorvastatin Versus Atorvastatin in Patients With High Cholesterol Not Controlled on Atorvastatin 40 mg (0653-090)

Phase 3

Completed

Conditions: Hypercholesterolemia

Interventions: Drug: atorvastatin
Drug: ezetimibe

First Posted Date: 2006-01-13

Last Posted Date: 2024-05-14

Lead Sponsor: Organon and Co

Target Recruit Count: 579

Registration Number: NCT00276484

High-dose Periop Statins for Prevention of DVT

Not Applicable

Completed

Conditions: Gynecologic Oncological Pelvic/Abdominal Surgery

First Posted Date: 2005-11-29

Last Posted Date: 2016-12-01

Lead Sponsor: Yale University

Target Recruit Count: 29

Registration Number: NCT00259662

Locations: 🇺🇸
Yale-New Haven Hospital, New Haven, Connecticut, United States

Atorvastatin Therapy for the Prevention of Atrial Fibrillation (SToP-AF)

Phase 3

Terminated

Conditions: Inflammation
Atrial Fibrillation

Interventions: Drug: Placebo
Drug: Atorvastatin

First Posted Date: 2005-11-15

Last Posted Date: 2014-09-03

Lead Sponsor: Emory University

Target Recruit Count: 64

Registration Number: NCT00252967

Locations: 🇺🇸
The Emory Clinic, Atlanta, Georgia, United States
🇺🇸
Veteran Administration Medical Center/Emory University, Atlanta, Georgia, United States
🇺🇸
Crawford Long Hospital, Atlanta, Georgia, United States

Study to Compare the Efficacy of Pitavastatin With That of Atorvastatin in Lowering Cholesterol Levels

Phase 3

Completed

Conditions: Primary Hypercholesterolemia
Dyslipidemia

First Posted Date: 2005-11-07

Last Posted Date: 2010-01-12

Lead Sponsor: Kowa Research Europe

Target Recruit Count: 830

Registration Number: NCT00249249

Locations: 🇳🇴
Rikshospitalet - University Hospital, Oslo, Norway
🇳🇴
Skedsmo Medisinske Senter A.S., Skedsmokorset, Norway
🇮🇳
Sir J. J. Group of Hospitals, Maharashtra, India

and more 187 locations

Early Therapeutic Effects of Statins and Fibrates on Unstable Atherosclerotic Plaques

Phase 4

Withdrawn

Conditions: Atherosclerosis

First Posted Date: 2005-10-24

Last Posted Date: 2007-11-19

Lead Sponsor: University Hospital Muenster

Target Recruit Count: 100

Registration Number: NCT00243672

Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary Syndrome (JAPAN-ACS)

Phase 4

Completed

Conditions: Coronary Disease
Hypercholesterolemia

Interventions: Drug: Atorvastatin
Drug: Pitavastatin

First Posted Date: 2005-10-21

Last Posted Date: 2023-10-04

Lead Sponsor: Kyoto University

Target Recruit Count: 307

Registration Number: NCT00242944

Locations: 🇯🇵
Juntendo University School of Medicine, Bunkyo-ku, Tokyo, Japan
🇯🇵
Yamaguchi University Graduate School of Medicine, Ube, Yamaguchi, Japan
🇯🇵
Kyoto University Graduate School of Medicine, Kyoto, Japan